
News|Articles|February 3, 2025
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
Author(s)PurpleLab
A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
Trending on Applied Clinical Trials Online
1
The CRA of the Future: From Monitoring Activity to Strategic Site Partnership
2
ACT Brief: Data Standardization Bottleneck in Real-Time Monitoring, US Biotech FIH Trial Regulatory Frustration, and FDA Approval of Zenbexus for Multiple Myeloma
3
One Clinical: Working Together to Advance Trial Collaboration
4
Closing the Dead Time Gap in Clinical Data: Q&A with Raviv Pryluk, PhaseV
5